Clinical reports have highlighted a role for retinoids in the etiology of mood disorders. Although we had shown that recruitment of the nuclear receptor retinoic acid receptor-α (RAR-α) to corticotropin-releasing hormone (CRH) promoter is implicated in activation of the hypothalamus-pituitary-adrenal (HPA) axis, further insight into how retinoids modulate HPA axis activity is lacking. Here we show that all-trans retinoic acid (RA)-induced HPA activation involves impairments in glucocorticoid receptor (GR) negative feedback. RA was applied to rats chronically through intracerebroventricular injection. A 19-day RA exposure induced potent HPA axis activation and typical depression-like behavior. Dexamethasone failed to suppress basal corticosterone (CORT) secretion, which is indicative of a disturbed GR negative feedback. In the hypothalamic paraventricular nucleus, increased CRH + and c-fos + cells were found while a negative R−2 + ∕ER + correlation was present between the number of RAR-α + and GR + cells. This was paralleled by increased RAR-α and decreased GR protein expression in the hypothalamus. Additional in vitro studies confirmed that RA abolished GR-mediated glucocorticoid-induced suppression of CRH expression, indicating a negative cross-talk between RAR-α and GR signaling pathways. Finally, the above changes could be rapidly normalized by treatment with GR antagonist mifepristone. We conclude that in addition to the 'classic' RAR-α-mediated transcriptional control of CRH expression, disturbances in GR negative feedback constitute a novel pathway that underlies RA-induced HPA axis hyperactivity. The rapid normalization by mifepristone may be of potential clinical interest in this respect.
INTRODUCTION
The retinoid family comprises vitamin A, its metabolite 13-cisretinoic acid (13-cis-RA) and all-trans retinoic acid (RA). 13-cis-RA reaches bioactivity mostly via isomerization to RA, which has a high affinity for the nuclear receptor retinoic acid receptor (RAR). 1 Emerging evidence demonstrate that retinoids are essential for the developing [2] [3] [4] as well as adult brain. [5] [6] [7] Through dietary vitamin A consumption or treatment of severe acne with 13-cis-RA, excessive retinoid intake in humans has been implicated in mood disorders like depression. Evidence are from abundant clinical case reports uncovering the association between retinoid treatment and depressive symptoms. [8] [9] [10] [11] Recently, abnormal endogenous retinoid signaling has also been found in the brain of depressed patients. 12, 13 In the paraventricular nucleus (PVN) of patients with affective disorders, both the density of RAR-α-immunoreactive (IR) neurons and the numbers of corticotropinreleasing hormone (CRH)-RAR-α double-stained neurons were found to be significantly increased. 12 Moreover, compromised RA and BDNF-TrkB signaling was found in the prefrontal cortex of mood disorder patients, which was supported by a reduced expression of the key elements of RA synthesis and metabolism in the dorsolateral prefrontal cortex/anterior cingulate cortex of elderly depressed patients. 13 Hypothalamus-pituitary-adrenal (HPA) axis hyperactivity is often seen in depressive patients. 14 CRH plays a central role in controlling stress response and regulating HPA axis activity. 15 Previously, we had shown that RAR-α upregulates CRH gene expression by its recruitment to the CRH promoter. 12 Chronic RA treatment further induces HPA axis hyperactivity and anxietyrelated behavior. 16 These findings provided an essential underlying mechanism for the involvement of RA in the pathophysiology of depression. Fine-tuning the regulation of HPA axis activity through glucocorticoid receptor (GR)-mediated negative feedback is essential for adaptation to stress. 17, 18 The peripheral impairments in GR negative feedback and elevations in basal cortisol levels that are paralleled by a central overproduction of CRH and vasopressin are prominent features in neuropsychiatric disorders.
In the present study, we investigated: (i) whether acute RA infusion alters plasma CORT levels through RAR-α; (ii) whether chronic RA administration modulates HPA axis activity and induces any depression-like behavior via alterations in GR negative feedback; (iii) possible effects of RA on GR-mediated glucocorticoid suppression of CRH expression in vitro; and finally, (iv) whether these parameters can be normalized by treatment with the GR antagonist mifepristone (RU38486).
MATERIALS AND METHODS Animals
All animal experiments and procedures were approved by the animal ethical committee of University of Science and Technology of China and in accordance with the guide for care and use of laboratory animals of the National Institutes of Health. A total of 66 male adult Sprague-Dawley rats (8-10 weeks of age, 300-350 g) were housed under controlled conditions of a 12/12-h light/dark cycle with a standard diet and water ad libitum and were handled daily for one week before experiments started. Twelvehour light cycle in the animal room was from 0700 to 1900. Temperature and humidity were kept constant (20-22°C and 50-55%, respectively).
Details for the acute experiment study are provided in Supplementary Methods.
For the chronic experiment, 36 rats were assigned either to a vehicle (VEH; n = 12), RA (n = 12), vehicle plus mifepristone (VEH+MIF; n = 6) or a RA plus mifepristone group (RA+MIF; n = 6). Among the 36 rats, 24 rats (n = 6 for each treatment group) were used for plasma corticosterone (CORT) evaluation, behavioral tests and subsequent immunohistochemical study. The other 12 rats (n = 6 for each VEH and RA group) were used for western blot analysis of brain hypothalamic samples.
I.c.v. surgery I.c.v. surgery was performed 7 days before drug administration. With standard Kopf stereotaxic apparatus, a guide cannula was placed into the lateral cerebral ventricle (anterior posterior, 1.0 mm; lateral, 1.5 mm; 3.5 mm ventral from dura). Intravenous cannulation of the right jugular vein was performed according to previously described methods. 32 All probe locations were verified in thionin-stained 40-μm cryostat sections. Only animals with a correct probe placement were used for data analysis.
Drug administration and blood sampling
Drug administration was performed manually by inserting an infusion probe cannula connected to either a Hamilton syringe (chronic model) or a syringe pump (acute model). Blood was sampled from an intravenous cannula in a sound-isolated room with minimal disturbance. Blood samples of 0.2 ml were replaced with equivalent volumes of heparinized saline.
For the chronic treatment, drugs were given daily between 0900 and 0930. The RA group received 20 μg RA (Sigma-Aldrich, St Louis, MO, USA) dissolved in 2 μl 1:1 v/v dimethyl sulfoxide (DMSO):saline avoiding light exposure 16, 33 once daily for 19 consecutive days. The VEH group received 2 μl 1:1 v/v DMSO:saline each day. Mifepristone treatment groups received 100 ng mifepristone (Sigma-Aldrich), 34 without (VEH+MIF group) or with 20 μg RA together (RA+MIF group), which was dissolved in 2 μl 1:1 v/v DMSO:saline and injected daily during the last 5 days. At 45 min before the last day drug injection, blood samples were collected.
Stress effects on HPA activity
Animals were subjected to a 10-min forced swimming stress at 1530, that is, 6 h after the last chronic drug injection. 35 Blood samples were collected immediately after stress. After sampling, rats were dried and warmed for 15 min.
Dexamethasone (DEX) suppression test (DST)
The next day after chronic drug treatment, DEX (Sigma-Aldrich; 100 μg in 0.1 ml saline) 36 was injected through an intravenous cannula at 0900 hours. Blood samples were collected before DEX injection for a basal value (t = 0 min) and then sequentially at t = 45 min and t = 90 min. At t = 90 min, animals were subjected to acute stress (10-min forced swimming). CORT levels were examined directly after stress termination (t = 100 min), and subsequently at t = 110 min and 130 min.
Depression/anxiety-related behavioral tests All behavioral tests were performed between 0800 and 0000 hours after 20 min adaptation. Twenty-four chronically treated rats (n = 6 for each of the four groups) were tested. Detailed procedures for open-field test are shown in the Supplementary Methods.
Sucrose preference test
The sucrose preference test was performed at 1130 on the same day after the DST and before the other behavioral tests. Animals were trained to drink 1% (w/v) sucrose solution for 24 h. The next day, they were given free access to two bottles containing normal water and sucrose solution. To avoid left/right preference, bottle order (left-right placement of water vs sucrose) was alternated for each rat during the middle of both the adaptation and testing period. Bottles were weighed at the beginning and end of the testing period of 24 h. The percentage of sucrose solution from total liquid consumed during 24 h was measured for anhedonia, a core symptom of 'depression-like behavior'. 37 
Elevated plus maze
The elevated plus maze test evaluates anxiety-related behavior. 16, 38, 39 Rats were placed in the central arena of a black plus-shaped maze, facing an open arm and were left to explore for 5 min. The duration and frequency at which open arms were explored was analyzed by video camera and processed by EthoVision (Noldus, Wageningen, The Netherlands).
Open-field test
Details for the open-field tests are provided in the Supplementary Methods.
Plasma CORT
Blood samples were collected in heparin-coated tubes, immediately chilled on ice and centrifuged at 4000 r.p.m. for 15 min at 4°C. Plasma was stored at −80°C for measuring plasma CORT using an enzyme-linked immunosorbent assay kit (RapidBio Lab, Calabasas, CA, USA).
Brain tissue, immunohistochemistry and image acquisition
For killing, all animals were anesthetized in the morning (0900-1100) with sodium pentobarbital (1 mg/kg) in individual cages. After behavioral tests, the 24 chronically treated rats (n = 6 for each group) were perfused transcardially with saline followed by 4% paraformaldehyde. Brains were cryoprotected in 30% sucrose before sections (40 μm thick) were cut. Another 12 chronically treated rats (n = 6 for each VEH and RA group) were quickly decapitated the next day after the last day chronic drug injection. Hypothalami were dissected according to literature 40 before being quickly frozen in liquid nitrogen and stored at −80°C.
Immunohistochemical staining of each marker was performed in every eighth section taken along the rostrocaudal axis throughout PVN according to standard procedures, 41 with primary antibodies of anti-CRH (rabbit, 1:2000; Bachem, Torrance, CA, USA), anti-c-fos (rabbit, 1:800; Santa Cruz, Santa Cruz, CA, USA), anti-RAR-α (rabbit, 1:100; Abcam, Cambridge, UK) and anti-GR (rabbit, 1:200; Santa Cruz). Information on antibody specificity has been provided in the Supplementary File. Amplification was performed with biotinylated goat-anti-rabbit secondary antibodies (1:200; Vector Laboratories, Burlingame, CA, USA) and avidin-biotin complex (1:800; Vector Laboratories). Chromogen development was performed with diaminobenzidine. Photographs were collected using a Nikon E800u microscope (Nikon, Tokyo, Japan) and a Canon Digital camera (PowerShot S40, Canon, Tokyo, Japan). Immunopositive cells were counted manually at a ×100 magnification, which was followed by confirmation at ×400 magnification (for details see Supplementary Methods) by an investigator blind to the experimental conditions. 16, 42 Western blot Hypothalamic samples were used to quantify RAR-α and GR protein as described. 12 Protein samples were detected with anti-RAR-α (rabbit, 1:500; Santa Cruz) and GR primary antibody (rabbit, 1:50 000; Abcam) and then horseradish peroxidase-conjugated goat-anti-rabbit IgG (1:2000; Promega, Madison, WI, USA), using horseradish peroxidase-conjugated β-actin (KC-5A08, 1:2000; Kangchen, Shanghai, China) as internal control. Signals were detected with an ECL chemiluminescence system (SuperSignal West Pico chemiluminescent Substrate, Pierce, IL, USA). Immunoblots were quantified using a high-resolution scanner. Background subtraction was performed and density was calculated using ImageJ software (Wayne Rasband, National Institute of Mental Health, Bethesda, MD, USA). Results were expressed as percentage of β-actin.
In vitro studies
The human neuroblastoma BE(2)C cell line expressing CRH, both intrinsically and upon RA treatment, 43, 44 was cultured with Dulbecco's modified Eagle's medium/F12 (DF; Sigma, St Louis, MO, USA) supplied with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA). Cultures were maintained at 37°C in 5% CO2 and a humidified atmosphere.
GR-mediated glucocorticoid repression of CRH gene expression
As GR is not endogenously expressed in BE(2)C cells, 45 a transient transfection was performed with previously tested 6RGR-based rat GR-α plasmid. 46, 47 Twenty-four hours after plating, cells were transfected with 0.3 μg GR-α or an empty plasmid (NE) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Four hours after transfection, culture media were changed to phenol red-free DF containing 10% FBS and 1 μM RA or VEH (0.1% DMSO in final volume) with or without 100 nM DEX or/and 100 nM mifepristone. 1 μM RA, 12 100 nM DEX 45 and 100 nM mifepristone 48 were dissolved in 0.1% DMSO and diluted in DF with 10% FBS before application. Cells were harvested 24 h later.
Real-time quantitative RT-PCR analysis
CRH mRNA expression was analyzed with β-actin as internal control. Total RNA was extracted using Trizol extraction (Invitrogen). cDNA was synthesized using reverse transcriptase (Promega). Real-time quantitative RT-PCR was performed using SYBR Green Mix (Takara, Dalian, China) and amplified with an ABI Prism 7000 system (Applied Biosystems, Foster City, CA, USA). The following upper and lower primers were used: human CRH (NM_000756) forward: 5′-CATCTCCCTGGATCTCACCTTC-3′ reverse:
5′-AATAATCTCCATGAGTTTCCTGTTG-3′; human β-actin (NM_001101 65) forward: 5′-CCCAGCCATGTACGTTGCTA-3′ reverse: 5′-TCACCGGAGTCCATC ACGAT-3′. The relative amount of target gene was calculated using the 2 − ΔΔCt method. 
RESULTS
Acute treatment study Plasma CORT concentration changes in response to time during a 2-h acute infusion of each drug are shown in Supplementary Figure S1 .
Chronic treatment study Basal and stress-induced CORT changes and depression/anxietyrelated behavior. The experimental schedule of chronic treatment study is described in Figure 1a . Body weight changes after chronic drug treatment were compared among the four groups (Supplementary Figure S2) . Effects of chronic RA-induced alterations in the stress response were evaluated. Under basal conditions, significantly different CORT levels were found among the VEH, RA, VEH+MIF and RA+MIF groups (F(3,16) = 6.916, P = 0.003) (Figure 1b) . Post-hoc analysis revealed the basal CORT concentration in the RA group to be higher than that in the VEH group (P = 0.003); mifepristone treatment significantly normalized basal CORT values in the RA group (P = 0.014 RA+MIF vs RA) but mifepristone alone had no effect (P = 0.586 VEH+MIF vs VEH). As shown in Figure 1c , under acute stress, CORT concentration is significantly higher in the RA compared with VEH group (F(1,8) = 24.557, P = 0.001).
A difference in sucrose uptake was found among the four groups (F(3,19) = 5.318, P = 0.008; Figure 1d ). Sucrose preference in RA group was significantly decreased compared with VEH group (P = 0.01). Remarkably, the RA-induced decrease in sucrose uptake was normalized by mifepristone (P = 0.03 RA+MIF vs RA). Mifepristone alone was ineffective (P = 0.594 VEH+MIF vs VEH).
In the elevated plus maze experiment, a significant difference in both entry frequency (F(3,19) = 3.890, P = 0.025) and duration percentage in open arms (F(3,19) = 6.567, P = 0.003) was found among the four groups (Figures 1e and f) . Both parameters were significantly decreased in the RA compared with VEH group (P = 0.048 and P = 0.004, respectively), which were again normalized by mifepristone (P = 0.043 and P = 0.034 RA+MIF vs RA). Mifepristone itself had no effect on both parameters (P = 1.000 and P = 0.623 VEH+MIF vs VEH).
Results of the open-field experiment are shown in Supplementary Figure S3 .
DST. To examine the GR-mediated glucocorticoid-negative feedback, we analyzed HPA changes by chronic RA exposure before and after stress under conditions of a DEX challenge. The design of the DST is shown in Figure 2a .
Under basal conditions, DEX treatment significantly suppressed plasma CORT concentration (time effect, F(2,9) = 6.723, P = 0.016); this effect was significantly different among groups (group effect, F(3,27) = 82.023, P o 0.001; Figure 2b ). In the VEH group, basal CORT secretion significantly differed by time (F(2,9) = 8.266, P = 0.009); CORT was suppressed significantly at both t = 45 min (P = 0.037) and t = 90 min (P = 0.009) compared with t = 0 min. However, this was not observed in the RA group (F(2,9) = 2.478, P = 0.139). Basal CORT secretion differed over time also in the VEH+MIF group (F(2,9) = 11.728, P = 0.003), where CORT was suppressed at t = 45 min (P = 0.003 vs t = 0 min) but not at t = 90 min (P = 0.278 vs t = 0 min). In the RA+MIF group, also a significantly different time effect was found (F(2,9) = 10.843, P = 0.004): CORT was suppressed at both t = 45 min (P = 0.005) and t = 90 min (P = 0.012) compared with t = 0 min. The above results indicate an impaired GR negative feedback in RA-treated rats, which could be normalized by mifepristone.
Acute stress altered plasma CORT concentration significantly (time effect, F(2,9) = 48.03, P o 0.001). Again, a significant treatment effect was found (group effect, F(3,27) = 26.13, P o0.001); time × group effect (F(6, 27) = 6.099, P o0.001). In detail, after acute stress, both VEH and RA groups showed significant time effects (F(2,9) = 29.676, Po 0.001 and F(2,9) = 6.746, P = 0.016, respectively). However, increased CORT was found in the VEH (P o 0.001) but not in the RA group (P = 0.765) at t = 110 min compared with t = 100 min. A decrease in CORT was found in the RA (P = 0.017) but not in the VEH group (P = 0.054) at t = 130 min compared with t = 110 min. Both VEH+MIF and RA+MIF groups showed significant time effects (F(2,9) = 5.206, P = 0.031 and F (2,9) = 22.553, P o 0.001, respectively). Both groups showed increased CORT concentrations at t = 110 min (P = 0.043 and Po 0.001 vs t = 100 min), but only RA+MIF group showed decreases in CORT at t = 130 min compared with t = 110 min (P = 0.016). The rapid rise in CORT after stress, even after a DEX challenge in RA-treated rats, is thus indicative of a hyperactive HPA axis. The immunoreactive cells for CRH, c-fos, RAR-α and GR in the PVN were quantified to compare differences among the groups. As shown in Figure 3e , a significantly different CRH-IR cell number Figure 2 . Dexamethasone (DEX) suppression test (DST). (a) Protocol of the DST. Blood sample was first collected immediately before a DEX injection (t = 0 min, intravenous injection of 100 μg DEX in 0.1 ml saline) and then sequentially at 45 min (t = 45 min) and 90 min (t = 90 min) after DEX injection. At 90 min after DEX injection (t = 90 min), an acute stress challenge (10 min forced swimming) was given. Blood was collected immediately after stress termination (t = 100 min) and then sequentially at 10 min and 30 min after stress termination (t = 110 and 130 min, respectively). (b) Plasma corticosterone (CORT) concentration changes in response to time after DEX injection and 10 min acute stress were compared among the four chronic treatment groups: vehicle (VEH) group, all-trans retinoic acid (RA) group, VEH plus mifepristone (VEH+MIF) group and RA plus mifepristone (RA+MIF) group. Data are presented as mean ± s.e.m. (n = 6 animals per group). *P o0.05; **P o0.01 (significantly different within group compared at t = 45 min vs t = 0 min and at t = 90 min vs t = 0 min); a: P o0.05 (significantly different within group compared at t = 110 min vs t = 100 min); b: P o0.05 (significantly different within group compared at t = 130 min vs t = 110 min).
Changes of CRH, c-fos, RAR-α and GR immunoreactivity in the PVN
Retinoic acid induces GR dysregulation P Hu et al was found among groups (F(3,20) = 3.944, P = 0.023). CRH-IR cell number was higher in the RA than in the VEH group (P = 0.047), which was normalized by mifepristone treatment (P = 0.025 RA-MIF vs RA). Similar results were found for the c-fos-IR cells (F(3,20) = 5.547, P = 0.006) that were significantly increased in the RA vs VEH group (P = 0.018), and also normalized by mifepristone (P = 0.028 RA+MIF vs RA) (Figure 3f ). Figure 3g shows differences in RAR-α-IR cell numbers between groups (F(3,20) = 20.056, P o 0.001). RAR-α-IR cells were significantly increased in the RA group (P o 0.001 vs VEH), which was normalized by mifepristone (P o 0.001 RA+MIF vs RA). The number of GR-IR cells was also significantly different among groups (F(3,20) = 5.544, P = 0.006). GR-IR cells were significantly decreased in the RA compared with the VEH group (P = 0.006); this was again normalized by mifepristone (P = 0.03 RA+MIF vs RA; Figure 3h ). For all the four markers examined, mifepristone treatment alone was ineffective (all P>0.05, VEH+MIF vs VEH). Figure 3i shows western examples of RAR-α and GR protein expression in the hypothalamus of chronic VEH vs RA group. Consistent with the immunohistochemistry, RAR-α density based on isolations from the hypothalamus of RA group (n = 6, 126.27 ± 11.53% of β-actin) was significantly increased compared with the VEH group (n = 6, 68.36 ± 4.65%, P o 0.01; Figure 3j ). In contrast, GR density in the hypothalamus of the RA group (n = 6, 112.45 ± 3.76% of β-actin) was significantly decreased compared with the VEH group (n = 6, 177.64 ± 5.85%, P o 0.01; Figure 3k ).
Correlations between RAR-α-and GR-immunopositive cell numbers and between sucrose preference and plasma CORT. We next examined the relationship between the number of RAR-α-IR and GR-IR cells in the PVN. Figure 4a shows a significant negative correlation between the RAR-α-IR and GR-IR cell numbers in the hypothalamic PVN (correlation coefficient R = − 0.394, P = 0.016).
To investigate potential effects of plasma CORT on depressive behavior, we examined the correlation between sucrose preference (a measure for anhedonia, core symptom of depression) and corresponding plasma CORT levels, that was also found significantly negative (correlation coefficient R = − 0.933, P o0.001; Figure 4b ).
In vitro studies GR-mediated glucocorticoid repression of CRH mRNA in BE(2)C cells. In vitro studies were performed to address how RA modulates GR-mediated suppression of CRH expression. Figure 5a shows that RA treatment significantly increased CRH mRNA expression in BE(2)C cells (both NE RA vs NE VEH and GR RA vs GR VEH, P o 0.001); DEX treatment alone had no effect (NE DEX vs NE VEH, P = 0.273). Under conditions of GR overexpression, DEX significantly decreased CRH expression (GR DEX vs NE DEX, P o0.001); whereas in the presence of RA, such inhibition was abolished (GR DEX RA vs NE DEX RA, P = 0.153). Mifepristone significantly normalized the attenuated DEX repression of CRH expression by RA (GR DEX RA MIF vs GR DEX RA VEH, Po 0.05). VEH of mifepristone alone had no effect (GR DEX RA VEH vs GR DEX RA, P = 0.805).
Together, RA abolished the GR-mediated repression of CRH expression by glucocorticoids, an effect that can be restored by co-treatment with the GR antagonist mifepristone (illustrated by the model shown in Figure 5b ).
DISCUSSION
Following our earlier demonstration that RAR-α upregulates CRH expression, 12 we now show that disturbed GR negative feedback is involved in RA-induced HPA hyperactivity. We demonstrate that (i) acute RA infusion elevates CORT secretion through RAR-α; (ii) chronic RA treatment increased CRH and decreased GR expression in the hypothalamic PVN, indicative of impaired HPA feedback inhibition; (iii) RA abolished GR-mediated repression of CRH expression by glucocorticoids in vitro, indicating a negative cross-talk between RAR-α and GR signaling; (iv) the RA-induced HPA hyperactivity, CRH overexpression and disturbances in GR negative feedback could all be quickly normalized by treatment with the GR antagonist mifepristone.
Clinical basis of the current study In humans, accutane (13-cis-RA or isotretinoin) is usually used orally at 0.5-2.0 mg kg − 1 per day over a 4-month treatment period. Clinical evidence shows that treatment with 13-cis-RA in a restricted dose range as low as 0.5-1 mg kg − 1 per day can cause depression in susceptible individuals. 8, 11, 50 In adult mice, when given at a clinical dose of 1 mg kg − 1 by daily intraperitoneal (i.p.) injection for 3-6 weeks, 13-cis-RA produces depression-related behavior 9 and suppresses hippocampal-dependent learning. 51 Our previous work had revealed that hyperactivation of HPA axis occurs after applying RA at a dose at the upper limit of what is used for clinical treatment of acne (2 mg kg − 1 per day), which translated into daily i.p. injection of young rats for 6 weeks. 16 In the current study, to ensure an efficient and direct incorporation into the brain, we performed an i.c.v. injection of 20 μg RA into adult rats daily for 19 days at a dose 30-40 times lower than by systemic i.p. injection. This dose is also based on a reported neuroprotective i.c.v. dosage of 9-cis-RA. 33 Our results with this dose show comparable effects on the activation of HPA axis.
Decreased expression of GR in hypothalamus contributes to RAinduced deficient HPA negative feedback Activation of the HPA axis is driven by CRH neurons in the hypothalamic PVN. 52 The increased c-fos expression that occurred particularly in the parvocellular portion of the PVN after chronic RA exposure indicates CRH neurons are activated, as confirmed by CRH immunostaining. In addition, the DEX non-suppression profile is consistent with an impaired GR negative feedback. Our hypothesis that the GR links RA signaling and HPA hyperactivity is further supported by the negative correlation between the RAR-α-IR and GR-IR cell numbers in the PVN, and by the increased RAR-α and decreased GR protein expression in the hypothalamus. Moreover, co-localization of RAR-α and GR in the PVN (our unpublished data), a primary target region for glucocorticoidmediated negative feedback and HPA suppression, [53] [54] [55] may further suggest the existence of a complex local RA-glucocorticoid signaling cross-talk. As the GR is pivotal for both DEX suppression of CRH transcription 44, 56 and stress reactivity control, [57] [58] [59] decreased expression of hypothalamic GR is indicative of a disinhibition of the HPA axis. In turn, this may result in hypothalamic CRH Negative cross-talk between RAR-α and GR signaling Our in vitro experiment suggests that RA abolished the GR-mediated suppression of CRH expression by glucocorticoid, compatible with a negative cross-talk between RAR-α and GR signaling transduction systems. In a situation of GR overexpression, activated RAR-α might interfere with formation of the GR repressing complex on the nGRE of the CRH promoter, presumably by either preventing the recruitment of co-repressors 62 or destabilizing the repressing complex. In support of this view, ligated RAR-α was recently found to co-immunoprecipitate with ligated GR and to physically interact directly in thymocytes. 63 A similar mechanism of direct proteinprotein interaction and tethering of GR and AP-1 (c-Jun/c-Fos) has been suggested to contribute to their mutual transcriptional repression. 64 Thus, we propose that RA may act as a de-repressor of GR transcriptional repression at CRH promoter, and hence lead to CRH overexpression. However, the precise molecular mechanism by which such regulation occurs at the transcriptional level awaits future study.
Mifepristone restored the impaired GR negative feedback The negative correlation we found between the sucrose preference percentage and the plasma CORT levels suggests excess cortisol could mediate depressive symptoms like anhedonia. Blocking this response might be beneficial; and indeed mifepristone has been shown to be beneficial in patients with Cushing's disease or psychotic depression [65] [66] [67] [68] [69] [70] and in stressrelated readouts in rodent models, 41, 71, 72 notably already following a brief treatment. We here administered mifepristone for 5 days to be consistent with previous basic and clinical studies. The present normalized c-fos activation in the PVN by mifepristone suggests a restoration of intrinsic central cellular components of the HPA axis. Mifepristone may reinstate the sensitivity of GR negative feedback through a rapid normalization of GR expression within the PVN, as shown in Figure 3h . Such a facilitation in HPA feedback inhibition has been documented before. 73 Additionally, in vitro studies confirmed that mifepristone can restore GR function in repressing CRH transcription, suggesting its partial agonist properties. 74, 75 Mifepristone was reported to actively recruit specific co-repressors to the GR, 74 which would lead to a more tight conformation of GR bound to specific GREs. 76 Furthermore, as a GR antagonist with strong affinity to GR, it could effectively block the depressive behavioral consequences of excessive CORT by preventing transactivation of GR-responsive genes. 77 GR blockade may further stimulate the function of mineralocorticoid receptor (MR), which contributes to tonic inhibitory control of the HPA axis. 17 However, while traditionally known for its GR antagonistic activity, mifepristone also exerts effects on the progesterone receptor at lower concentrations and can influence the CRH system. 78 Thus, some observed results could result from its mixed pharmacological profile. Nevertheless, our current study showed that RA-induced HPA hyperactivity, disturbed GR negative feedback and CRH overexpression could all be rapidly normalized by treatment with mifepristone.
There are also several limitations in the present study. First, with regard to the in vitro effect, we only predicted potential modulation of mifepristone based on reported structural and conformational changes by interactions between GR and mifepristone. To test our hypothesis in detail, it would require extra work at molecular level, such as identification of critical aminoacid residues involved. Second, we performed i.c.v. injection of RA at a single dose (20 μg RA) daily for 19 days. Further comparison of varying doses to understand its efficacy range awaits future study.
Taken together, we propose that RA activates the HPA axis through (i) an increased hypothalamic CRH production, mediated via RAR-α transcriptional activation; (ii) a deficient negative feedback at the level of hypothalamic GR expression, which implicates changes in GR sensitivity to underlie RA-induced hyperactivity of the HPA axis. In humans, such maladaptive changes in the HPA axis after excessive RA treatment or vitamin A consumption may set the stage for stress-related neuropsychiatric disorders. The rapid reversal by mifepristone may hence be of interest for the development of therapeutic options for HPArelated aspects of depression.
